Analysts’ Opinions Are Mixed on These Healthcare Stocks: NewLink (NASDAQ: NLNK), Array Biopharma (NASDAQ: ARRY) and Gilead Sciences (NASDAQ: GILD)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NewLink (NASDAQ: NLNK), Array Biopharma (NASDAQ: ARRY) and Gilead Sciences (NASDAQ: GILD).

NewLink (NASDAQ: NLNK)

Jefferies analyst Biren Amin reiterated a Hold rating on NewLink (NASDAQ: NLNK) on November 1 and set a price target of $12. The company’s shares closed yesterday at $10.86, close to its 52-week low of $9.23.

Amin noted:

“Mgmt reiterated many of the statements made on the analyst day last week. 2017 continues to be a key data catalyst year for indoximod with plans to initiate a PIII trial in 2H17.”

According to TipRanks.com, Amin is a 1-star analyst with an average return of -2.4% and a 35.3% success rate. Amin covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Anthera Pharmaceuticals, and Aquinox Pharmaceuticals.

NewLink has an analyst consensus of Moderate Buy.

Array Biopharma (NASDAQ: ARRY)

Jefferies analyst Eun Yang reiterated a Buy rating on Array Biopharma (NASDAQ: ARRY) on November 1 and set a price target of $8. The company’s shares closed yesterday at $5.84.

Yang wrote:

“Narrower net loss of ~$29M on higher revenue & lower OpEx; cash of $241M as of 10/3/16 sufficient into FY2019 by our est’s. With potentially 2 product launches in next 2 yrs (bini PDUFA date of 6/30/17 for NRASm melanoma, bini+enco regulatory submission in BRAFm melanoma in ~2H17), ARRY is transitioning into a commercial entity.”

According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -4.5% and a 43.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Array Biopharma is Strong Buy and the average price target is $8, representing a 37.0% upside.

In a report issued on November 1, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13 price target.
Gilead Sciences (NASDAQ: GILD)

Jefferies analyst Brian Abrahams reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD) on November 1 and set a price target of $91. The company’s shares closed yesterday at $72.51, close to its 52-week low of $72.21.

Abrahams wrote:

“Coming out of 3Q earnings, we continue to see oppty at the currently- depressed multiple, and believe that as the Street digests more realistic HCV tail assumptions the focus will more clearly shift to favorable HIV dynamics and progress with GILD’s underappreciated pipeline. We can get to DCF value of $91 (adjusted from $95) even with steep HCV declines, which reaffirms to us shares already assume an overly-bearish outlook with appreciation potential. Harvoni headwinds persist, particularly ex-U.S., as pt flows wane, though possible hints of price stabilization. U.S. Harvoni sales of $1.1B were just below our $1.2B est. as pt flows continue to decline– though mgmt commentary suggested share (at least pending add’l competitive entrants) and price/payer mix show signs of potential stabilization medium term. Poor ex-U.S. trends on volumes and price (even some seasonality) lead us to further reduce our out-yr ests. On the flip side, Epclusa/Sovaldi looked strong ($1.5B vs. $1.3B cons.), and though boosted by some warehousing, new Rx’s still look encouragingly stable to us.”

According to TipRanks.com, Abrahams is ranked 0 out of 5 stars with an average return of -5.2% and a 31.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Protalix Biotherapeutics.

Currently, the analyst consensus on Gilead Sciences is Moderate Buy and the average price target is $92, representing a 26.9% upside.

In a report issued on October 18, Robert W. Baird also reiterated a Buy rating on the stock with a $100 price target.